Alpha2-macroglobulin as a promising biomarker for cerebral small vessel disease in acute ischemic stroke patients

Journal of Neurology

Volumn 260, Issue 10, 2013, Pages 2642-2649

  Nezu, Tomohisa ^a   Hosomi, Naohisa ^a,b   Aoki, Shiro ^a   Deguchi, Kazushi ^b   Masugata, Hisashi ^b   Ichihara, Noriko ^c   Ohyama, Hideo ^d   Ohtsuki, Toshiho ^a   Kohno, Masakazu ^b   Matsumoto, Masayasu ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c National Hospital Organization Takamatsu Medical Center   (Japan)

^d Osaka Neurosurgical Hospital   (Japan)

Author keywords

Biological markers; Inflammation; Leukoaraiosis; Neurology; Stroke

Indexed keywords

ALPHA 2 MACROGLOBULIN;

AGED; ARTICLE; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; WHITE MATTER LESION;

AGED; AGED, 80 AND OVER; ALPHA-MACROGLOBULINS; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CEREBRAL SMALL VESSEL DISEASES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NERVE FIBERS, MYELINATED; ROC CURVE; STATISTICS, NONPARAMETRIC; STROKE;

EID: 84886099928     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-7040-x     Document Type: Article

References (34)

1. LaMarre J, Wollenberg GK, Gauldie J, Hayes MA (1990) Alpha 2-macroglobulin and serum preferentially counteract the mito-inhibitory effect of transforming growth factor-beta 2 in rat hepatocytes. Lab Invest 62:545-551
2. Sottrup-Jensen L (1989) Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 264:11539-11542
3. Herz J, Kowal RC, Ho YK, Brown MS, Goldstein JL (1990) Low density lipoprotein receptor-related protein mediates endocytosis of monoclonal antibodies in cultured cells and rabbit liver. J Biol Chem 265:21355-21362
4. Herz J, Strickland DK (2001) LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 108:779-784
5. Hoogendoorn H, Toh CH, Nesheim ME, Giles AR (1991) Alpha 2-macroglobulin binds and inhibits activated protein C. Blood 78:2283-2290
6. Cvirn G, Gallistl S, Koestenberger M, Kutschera J, Leschnik B, Muntean W (2002) Alpha 2-macroglobulin enhances prothrombin activation and thrombin potential by inhibiting the anticoagulant protein C/protein S system in cord and adult plasma. Thromb Res 105:433-439
7. Cvirn G, Gallistl S, Muntean W (2001) Effects of alpha(2)-macroglobulin and antithrombin on thrombin generation and inhibition in cord and adult plasma. Thromb Res 101:183-191
8. Beheiri A, Langer C, Düring C, Krümpel A, Thedieck S, Nowak-Göttl U (2007) Role of elevated alpha2-macroglobulin revisited: results of a case-control study in children with symptomatic thromboembolism. J Thromb Haemost 5:1179-1184
9. Arbeláez LF, Bergmann U, Tuuttila A, Shanbhag VP, Stigbrand T (1997) Interaction of matrix metalloproteinases-2 and -9 with pregnancy zone protein and alpha2-macroglobulin. Arch Biochem Biophy 347:62-68
10. Cáceres LC, Bonacci GR, Sánchez MC, Chiabrando GA (2010) Activated α(2) macroglobulin induces matrix metalloproteinase 9 expression by low-density lipoprotein receptor-related protein 1 through MAPK-ERK1/2 and NF-κB activation in macrophage-derived cell lines. J Cell Biochem 111:607-617
11. Matsuda T, Hirano T, Nagasawa S, Kishimoto T (1989) Identification of alpha 2-macroglobulin as a carrier protein for IL-6. J Immunol 142:148-152
12. Ahmad J, Singh M, Saleemuddin M (2001) A study of plasma alpha-2-macroglobulin levels in type 2 diabetic subjects with micro albuminuria. J Assoc Physic India 49:1062-1065
13. Watzke H, Schernthaner G, Schnack C, Schwarz HP, Prskavec F, Freyler H (1988) Coagulation factors of contact phase of haemostasis are normal in well-controlled type-I diabetic patients despite presence of diabetic retinopathy. Diabet Res 7:197-200
14. Hosomi N, Aoki S, Matsuo K, Deguchi K, Masugata H, Murao K, Ichihara N, Ohyama H, Dobashi H, Nezu T, Ohtsuki T, Yasuda O, Soejima H, Ogawa H, Izumi Y, Kohno M, Tanaka J, Matsumoto M (2012) Association of serum anti-periodontal pathogen antibody with ischemic stroke. Cerebrovasc Dis 34:385-392
15. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE (1993) Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke 24:35-41
16. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA (1987) MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol 149:351-356
17. Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J (1996) The ABCs of measuring intracerebral hemorrhage volumes. Stroke 27:1304-1305
18. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O (2004) Reference distributions for alpha2-macroglobulin: a comparison of a large cohort to the world's literature. J Clin Lab Anal 18:148-152
19. Patterson CC, Smith AE, Yarnell JW, Rumley A, Ben-Shlomo Y, Lowe GD (2010) The associations of interleukin-6 (IL-6) and downstream inflammatory markers with risk of cardiovascular disease: the caerphilly study. Atherosclerosis 209:551-557
20. Rehman AA, Ahsan H, Khan FH (2013) Alpha-2-macroglobulin: a physiological guardian. J Cell Physiol 228:1665-1675
21. Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Jolles J, Koudstaal PJ, Hofman A, Breteler MM (2005) Cerebral small-vessel disease and decline in information processing speed, executive function and memory. Brain 128:2034-2041
22. Pantoni L, Garcia JH (1997) Pathogenesis of leukoaraiosis: a review. Stroke 28:652-659
23. Fornage M, Chiang YA, O'Meara ES, Psaty BM, Reiner AP, Siscovick DS, Tracy RP, Longstreth WT (2008) Biomarkers of inflammation and MRI-defined small vessel disease of the brain: the cardiovascular health study. Stroke 39:1952-1959
24. Satizabal CL, Zhu YC, Mazoyer B, Dufouil C, Tzourio C (2012) Circulating IL-6 and CRP are associated with MRI findings in the elderly: the 3C-dijon study. Neurology 78:720-727
25. Pantoni L (2010) Cerebral small vessel disease: from pathogenesis to clinical characteristics to therapeutic challenges. Lancet Neurol 9:689-701
26. Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR, Weiner M, DeCarli C, Initiative AsDN (2010) Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol 67:1370-1378
27. Qiu WQ, Borth W, Ye Z, Haass C, Teplow DB, Selkoe DJ (1996) Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. J Biol Chem 271:8443-8451
28. Du Y, Ni B, Glinn M, Dodel RC, Bales KR, Zhang Z, Hyslop PA, Paul SM (1997) alpha2-macroglobulin as a beta-amyloid peptide-binding plasma protein. J Neurochem 69:299-305
29. Grinberg LT, Thal DR (2010) Vascular pathology in the aged human brain. Acta Neuropathol 119:277-290
30. Myllykangas L, Polvikoski T, Sulkava R, Verkkoniemi A, Crook R, Tienari PJ, Pusa AK, Niinistö L, O'Brien P, Kontula K, Hardy J, Haltia M, Pérez-Tur J (1999) Genetic association of alpha2-macroglobulin with Alzheimer's disease in a Finnish elderly population. Ann Neurol 46:382-390
31. Blacker D, Wilcox MA, Laird NM, Rodes L, Horvath SM, Go RC, Perry R, Watson B, Bassett SS, McInnis MG, Albert MS, Hyman BT, Tanzi RE (1998) Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat Genet 19:357-360
32. Poduslo SE, Shook B, Drigalenko E, Yin X (2002) Lack of association of the two polymorphisms in alpha-2 macroglobulin with Alzheimer disease. Am J Med Genet 110:30-35
33. Rudrasingham V, Wavrant-De Vrièze F, Lambert JC, Chakraverty S, Kehoe P, Crook R, Amouyel P, Wu W, Rice F, Pérez-Tur J, Frigard B, Morris JC, Carty S, Petersen R, Cottel D, Tunstall N, Holmans P, Lovestone S, Chartier-Harlin MC, Goate A, Hardy J, Owen MJ, Williams J (1999) Alpha-2 macroglobulin gene and Alzheimer disease. Nat Genet 22:17-19
34. Avilés-Santa L, Alpern R, Raskin P (2002) Reversible acute renal failure and nephrotic syndrome in a type 1 diabetic patient. J Diabetes Compl 16:249-254